Table 2.
Novel target in myeloma, agents and stage of ongoing clinical trials
| Cell surface targets | |||
|---|---|---|---|
| Target | Agent | Clinical Study Phase | Single Agent(S)/Combination(C) |
| FGF3 | Dasatinib | I/II | S |
| FGF, PDGF | (mAb)TKI258 | I | S |
| CD38 | mAb | I | S |
| CD40 | SGN-40 (mAb) | I/II | S, C (Lenalidomide) |
| HCD122 (mAb) | I | S | |
| CD56 | huN901-DM1 (C-mAb) | I | S |
| CS1 | HuLuc63 (mAb) | II/III | S, C (Lenalidomide, bortezomib) |
| CD138 | BT062 (mAb-DM4) | I | S |
| RANKL | AMG162 (mAb) | I/II | S |
| MUC1 | AR20.5 (mAb) | I/II | S |
| BAFFR | LY2127399 (mAb) | I/II | S |
| CD52 | Alemtuzumab (mAb) | II | S |
| TRAIL | Apo2L/TRAIL (Apo2 ligand) | I | S |
| Mapatumumab | I/II | S | |
| IGF1/R | IGF1R CP-571 (mAb) | I | S |
| EM164 (mAb) | I | S | |
| IL6/R | CNTO328 (mAb) | II/III | S, C (bortezomib) |
| Altizumab (mAb) | III | S | |
| VEGF/R | Bevacizumab (mAb) | II | S |
| SU5416 | II | S | |
| Zactima (ZD6474) | II | S | |
| DKK-1 | BHQ-880 | I/II | S |
| Activin A | I/II | S | |
| KIR | IPH101 | I/II | S |
| CXCR3 | AMD3100 | II | C (bortezomib) |
| Intracytoplasmic and/or nuclear targets | |||
| CDK | Alvocidib (NSC649890) | I | S |
| CDK and GSK3β | AT7519M | I/II | S, C (bortezomib) |
| IKK | RTA402 | I | S |
| Akt | perofosine | III | C (bortezomib) |
| HDAC | panabinostat | III | C (bortezomib) |
| Vorinostat | II/III | C (bortezomib) | |
| Romidopsin | II/III | C ( bortezomib) | |
| Farnesyltransferase | Tipifarnib (R115777) | II | S, C (bortezomib) |
| HSP90 | KOS953 | II | C ( bortezomib) |
| AUY922 | II | C (bortezomib) | |
| IPI504 | I/II | C (bortezomib) | |
| Proteasome | Carfilzomib | II/III | S, C (lenalidomide) |
| NPI-0052 | I | S | |
| MLN9708 | I | S | |
| Mitochondria | GCS-100 | I/II | C |
| mTOR | CCI-779 II | II | C (bortezomib) |
| RAD001 | II | C (lenalidomide, bortezomib) | |
| INK128 | II | S | |
| PKC | Enzastaurin | I/II | S, C (bortezomib) |
| Telomerease | GRN163L | I/II | S, C (bortezomib) |
Data collected from National Cancer Institute Clinical Trials website, Multiple
Myeloma Research Foundation website and the International Myeloma Foundation website. mAb, monoclonal antibody.